Skip to main content
    M

    MaxCyte Inc (MXCT)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $1.18
    -0.01 (-0.84%)

    Market Cap: $122.87M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    MaxCyte Inc (MXCT) Earnings: Report Dates and Results

    Updated Nov 10, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    MaxCyte (MXCT) is expected to report earnings on Mar 12, 2027. In the quarter ended Sep 30, 2026, MaxCyte reported EPS of -$0.05, above the -$0.08 estimate. It beat the EPS estimate in 6 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    70%(16/23)
    Avg Surprise
    +17.02%
    Streak
    5 Q

    Upcoming Estimates

    Reports Mar 12, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$0.08
    Range-$0.09 - -$0.05
    6 analysts
    Revenue Consensus
    $7.53M
    Range$6.96M - $7.98M
    7 analysts
    Report date not yet scheduledPeriod ending Mar 31, 2027
    EPS Consensus-$0.07
    Range-$0.07 - -$0.07
    2 analysts
    EPS RevisionsNo revisions (30d)
    EPS Estimate DriftChange to current
    90d ago-$0.070.0%
    60d ago-$0.070.0%
    30d ago-$0.070.0%
    7d ago-$0.070.0%
    Current-$0.07
    Revenue Consensus
    $8.11M
    Range$7.48M - $9.02M
    3 analysts

    Next Report

    MXCT has an expected report date of Mar 12, 2027.

    MXCT Earnings Call

    The latest MXCT earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 23 quarters below that had an estimate, MXCT beat 16, missed 3 and matched 4. Revenue for the quarter ended Sep 30, 2026 was $10.15M, up 48.6% from $6.83M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$0.05-$0.08-$0.09 - -$0.08+37.50%BeatN/A30 up, 1 downNov 10, 2026$10.15M
    Jun 30, 2026-$0.08-$0.12-$0.12 - -$0.08+33.33%BeatN/A30 up, 1 downAug 12, 2026$7.27M
    Mar 31, 2026-$0.04-$0.07N/A+31.69%BeatN/A20 up, 1 downMay 12, 2026$9.65M
    Dec 31, 2025-$0.06-$0.08-$0.09 - -$0.07+25.00%BeatN/A33 up, 1 downMar 24, 2026$7.30M
    Sep 30, 2025-$0.09-$0.10-$0.12 - -$0.07+10.00%BeatN/A50 up, 3 downNov 12, 2025$6.83M
    Jun 30, 2025-$0.12-$0.10-$0.11 - -$0.09-20.00%MissN/A50 up, 1 downAug 6, 2025$8.51M
    Mar 31, 2025-$0.10-$0.10-$0.12 - -$0.090.00%In lineN/A41 up, 0 downMay 7, 2025$10.39M
    Dec 31, 2024-$0.10-$0.12-$0.15 - -$0.10+16.67%BeatN/A40 up, 0 downMar 11, 2025$8.69M
    Sep 30, 2024-$0.11-$0.12-$0.15 - -$0.11+8.33%BeatN/A60 up, 0 downNov 6, 2024$8.16M
    Jun 30, 2024-$0.09-$0.13-$0.15 - -$0.12+30.77%BeatN/A60 up, 0 downAug 6, 2024$10.43M
    Mar 31, 2024-$0.09-$0.13-$0.15 - -$0.12+30.77%BeatN/A60 up, 0 downMay 7, 2024$11.34M
    Dec 31, 2023-$0.05-$0.07-$0.10 - -$0.05+28.57%BeatN/A50 up, 0 downMar 12, 2024$15.66M
    Sep 30, 2023-$0.11-$0.10-$0.11 - -$0.08-10.00%MissN/A50 up, 0 downNov 8, 2023$8.00M
    Jun 30, 2023-$0.10-$0.10-$0.12 - -$0.080.00%In lineN/A50 up, 0 downAug 9, 2023$9.04M
    Mar 31, 2023-$0.11-$0.11-$0.12 - -$0.110.00%In lineN/A50 up, 0 downMay 10, 2023$8.58M
    Dec 31, 2022-$0.05-$0.07-$0.08 - -$0.05+28.57%BeatN/A51 up, 0 downMar 15, 2023$12.42M
    Sep 30, 2022-$0.06-$0.08-$0.10 - -$0.06+25.00%BeatN/A51 up, 0 downNov 9, 2022$10.64M
    Jun 30, 2022-$0.08-$0.07-$0.09 - -$0.07-14.29%MissN/A50 up, 0 downAug 10, 2022$9.61M
    Mar 31, 2022-$0.04-$0.07-$0.07 - -$0.04+42.86%BeatN/A54 up, 0 downMay 9, 2022$11.59M
    Dec 31, 2021-$0.05-$0.05-$0.08 - -$0.020.00%In lineN/A50 up, 0 downMar 22, 2022$10.15M
    Sep 30, 2021-$0.03-$0.05-$0.07 - -$0.02+40.00%BeatN/A50 up, 0 downNov 10, 2021$10.14M
    Jun 30, 2021-$0.05-$0.06-$0.08 - -$0.05+16.67%BeatN/A4N/AJul 30, 2021$7.11M
    Mar 31, 2021-$0.07-$0.10N/A+30.00%BeatN/AN/AN/AJun 16, 2021$6.49M
    Dec 31, 2020-$0.09N/AN/AN/AN/AN/AN/AN/AMar 31, 2021$8.51M
    Sep 30, 2020-$0.04N/AN/AN/AN/AN/AN/AN/ADec 31, 2020$6.76M
    Jun 30, 2020-$0.04N/AN/AN/AN/AN/AN/AN/ASep 30, 2020$5.15M
    Dec 31, 2019-$0.05N/AN/AN/AN/AN/AN/AN/AMar 30, 2020$6.62M
    Sep 30, 2019-$0.03N/AN/AN/AN/AN/AN/AN/ADec 31, 2019$6.62M
    Jun 30, 2019-$0.03N/AN/AN/AN/AN/AN/AN/ASep 30, 2019$4.19M
    Mar 31, 2019-$0.09N/AN/AN/AN/AN/AN/AN/AJun 29, 2019$4.19M
    Dec 31, 2018-$0.09N/AN/AN/AN/AN/AN/AN/AMar 30, 2019$4.87M
    Sep 30, 2018-$0.04N/AN/AN/AN/AN/AN/AN/ADec 31, 2018$4.87M
    Jun 30, 2018-$0.04N/AN/AN/AN/AN/AN/AN/ASep 30, 2018$3.46M
    Mar 31, 2018-$0.05N/AN/AN/AN/AN/AN/AN/AJun 29, 2018$3.46M
    Dec 31, 2017-$0.05N/AN/AN/AN/AN/AN/AN/AMar 30, 2018$3.89M
    Sep 30, 2017-$0.06N/AN/AN/AN/AN/AN/AN/ADec 31, 2017$3.89M
    Jun 30, 2017-$0.06N/AN/AN/AN/AN/AN/AN/ASep 30, 2017$3.11M
    Mar 31, 2017-$0.05N/AN/AN/AN/AN/AN/AN/AJun 29, 2017$3.11M
    Dec 31, 2016-$0.05N/AN/AN/AN/AN/AN/AN/AMar 30, 2017$3.40M
    Sep 30, 2016-$0.02N/AN/AN/AN/AN/AN/AN/ADec 31, 2016$3.40M
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$0.37, after -$0.39 the year before. It was -$0.13 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$0.37N/A
    Dec 31, 2024-$0.39N/A
    Dec 31, 2023-$0.37N/A
    Dec 31, 2022-$0.23N/A
    Dec 31, 2021-$0.20N/A
    Dec 31, 2020-$0.16N/A
    Dec 31, 2019-$0.20N/A
    Dec 31, 2018-$0.21N/A
    Dec 31, 2017-$0.20N/A
    Dec 31, 2016-$0.13N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 7,800 words across 9 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20267,8359
    2026Q2Jun 30, 20265,75510
    2026Q1Mar 31, 20264,84612
    2025Q4Dec 31, 20256,49411
    2025Q3Sep 30, 20256,42710
    2025Q2Jun 30, 20255,2108
    2025Q1Mar 31, 20256,2109
    2024Q4Dec 31, 20245,81910

    2026Q3 Earnings Call

    Opening remarks

    Maher Masoud President and Chief Executive Officer Thank you, Erik. Hello, everyone, and thank you for joining MaxCyte's third-quarter 2026 earnings call. Before I turn to our results, I want to highlight the announcement we made today, which I believe is one of the most exciting moments in our company's history. Following a competitive process, we have entered into a definitive agreement to acquire Akron Bio from Arkline Investment Management. Akron Bio is a leading supplier of GMP-grade reagents and ancillary materials, including cytokines, growth factors, cell culture media, and cryopreservation solutions, used in the cell therapy manufacturing steps immediately before and after cell engineering, including electroporation. Akron Bio differentiates itself through its regulatory-grade quality and documentation, along with ready-to-use product formats that simplify and connect directly to cell therapy manufacturing workflows. Like MaxCyte, Akron Bio is specified in its customers' regulated processes, with drug master files, or DMFs, referenced in their IND and BLA submissions. Once specified in, which typically occurs in late-stage preclinical development, Akron Bio's products become increasingly difficult to displace as programs advance through clinical development and commercialization. Akron Bio supports four commercially approved therapies, including one with a leading global pharma company, and supports four additional programs with registrational pathways. With Akron Bio, MaxCyte triples its exposure to attractive commercial and registrational programs that are nearing approval. Beyond these late-stage assets, the combined company will be embedded in over 95 clinical-stage programs, including more than 85 from Akron Bio, providing a broad pipeline for potential future commercial opportunities. As part of our extensive diligence process, we conducted a detailed, program-by-program assessment of Akron Bio's portfolio, evaluating individual development timelines, progression toward commercialization, and long-term revenue opportunities. This bottom-up approach reinforced our conviction in the quality of its portfolio and its long-term growth potential. Akron Bio also brings meaningful scale, expanding our commercial revenue footprint and extending our reach across the cell therapy workflow, including both viral and nonviral therapies. Akron Bio's revenue is expected to be $28 million for 2026, and importantly, 80% to 85% of 2025 revenue was generated from specified-in customers, including 40% to 45% from commercial-stage customers. Both metrics highlight the durable and recurring nature of its revenue base. Furthermore, Akron Bio is expected to generate approximately $7 million to $8 million of EBITDA in 2026 and is cash-flow positive today, with an efficient cost structure. The acquisition will accelerate MaxCyte's path to profitability, which Parmeet will cover in more detail. Stepping back, I cannot be more excited by what this combination means for MaxCyte's next chapter.

    Frequently Asked Questions About MXCT

    When is MaxCyte's next earnings date?

    MaxCyte's next earnings report is expected for Mar 12, 2027.

    Did MXCT beat earnings estimates last quarter?

    Yes. MaxCyte reported EPS of -$0.05 for the quarter ended Sep 30, 2026, above the -$0.08 estimate, a 37.50% surprise.

    What EPS do analysts expect from MXCT next quarter?

    The consensus EPS estimate for MaxCyte for the quarter ending Dec 31, 2026 is -$0.08 from 6 analysts, with estimates from -$0.09 to -$0.05.

    How often does MXCT beat earnings estimates?

    MaxCyte beat the EPS estimate in 6 of the last 8 quarters, with an average surprise of +16.77%.